Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) inhibitors, offer a new treatment paradigm, though challenges remain. "An ...
- Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL ...
- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in December ...
Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations. Farmakidis explains how ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. This CME program is designed to enhance neurologists' ...
Details and references regarding individual diseases are provided in the Supplementary Appendix. CIDP denotes chronic inflammatory demyelinating polyneuropathy, Covid-19 coronavirus disease 2019, and ...
- Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potential capital across equity, royalty, and credit - - Successful October ...
- PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch - - Marketing Authorization Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results